Patheon Development Services, Inc.

? Evaluate the safety and tolerability of ZN-d5 in NHL subjects ? Determine the MTD and/or RP2D in NHL subjects ? Determine the PK characteristics of ZN-d5 in NHL subjects ? Evaluate the clinical activity of ZN-d5 in HNL subjects

To evaluate the effect of itraconazole, a strong inhibitor of cytochrome P450 3A (CYP3A), on the pharmacokinetics of ASC40 in healthy volunteers; to evaluate the effect of rifampicin, a strong inducer of CYP3A, on the pharmacokinetics of ASC40 in healthy volunteers; and to evaluate the safety and tolerability of ASC40 when itraconazole and rifampicin are used in healthy volunteers.

1. To determine the effect of TVB-2640 once daily (QD) for 12 weeks on the change from baseline in liver fat fraction in patients with nonalcoholic steatohepatitis (NASH), as measured by magnetic resonance imaging proton density fat fraction (MRI-PDFF), compared with placebo. 2. To determine the safety of TVB-2640 once daily compared with placebo in patients with NASH, including the effects on alanine aminotransferase (ALT) and aspartate aminotransferase (AST).